Varenicline Observational Investigation In The Cessation of Smoking

CompletedOBSERVATIONAL
Enrollment

567

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions
Smoking Cessation
Interventions
DRUG

Varenicline

According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.

Trial Locations (52)

1000

Pfizer Investigational Site, Ljubljana

1033

Pfizer Investigational Site, Budapest

1070

Pfizer Investigational Site, Brussels

1081

Pfizer Investigational Site, Brussels

1090

Pfizer Investigational Site, Jette

1134

Pfizer Investigational Site, Budapest

1160

Pfizer Investigational Site, Brussels

1230

Pfizer Investigational Site, Domžale

1380

Pfizer Investigational Site, Cerknica

1800

Pfizer Investigational Site, Vilvoorde

2000

Pfizer Investigational Site, Maribor

2030

Pfizer Investigational Site, Érd

2310

Pfizer Investigational Site, Rijkevorsel

2340

Pfizer Investigational Site, Beerse

2650

Pfizer Investigational Site, Edegem

3000

Pfizer Investigational Site, Leuven

Pfizer Investigational Site, Hatvan

3300

Pfizer Investigational Site, Eger

3545

Pfizer Investigational Site, Halen

3600

Pfizer Investigational Site, Genk

3720

Pfizer Investigational Site, Kortessem

4000

Pfizer Investigational Site, Liège

Pfizer Investigational Site, Kranj

4270

Pfizer Investigational Site, Jesenice

4400

Pfizer Investigational Site, Nyíregyháza

4432

Pfizer Investigational Site, Alleur

5000

Pfizer Investigational Site, Namur

5020

Pfizer Investigational Site, Vedrin

6031

Pfizer Investigational Site, Monceau-sur-Sambre

6720

Pfizer Investigational Site, Habay-la-Neuve

6800

Pfizer Investigational Site, Libramont-Chevigny

7090

Pfizer Investigational Site, Braine-le-Comte

8210

Pfizer Investigational Site, Zedelgem

8340

Pfizer Investigational Site, Moerkerke

8582

Pfizer Investigational Site, Farkasgyepű

8600

Pfizer Investigational Site, Siófok

8900

Pfizer Investigational Site, Zalaegerszeg

9000

Pfizer Investigational Site, Ghent

9310

Pfizer Investigational Site, Moorsel

9700

Pfizer Investigational Site, Szombathely

9800

Pfizer Investigational Site, Deinze

11527

Pfizer Investigational Site, Cholargós

11528

Pfizer Investigational Site, Ilisia

15126

Pfizer Investigational Site, Marousi

45500

Pfizer Investigational Site, Ioannina

56249

Pfizer Investigational Site, Thessaloniki

57010

Pfizer Investigational Site, Eksochi

65201

Pfizer Investigational Site, Kavala

68100

Pfizer Investigational Site, Alexandroupoli

71110

Pfizer Investigational Site, Heraklion

B-5530

Pfizer Investigational Site, Yvoir

41 110

Pfizer Investigational Site, Larissa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY